PT-141 (Bremelanotide)
The first FDA-approved centrally acting peptide for a sexual dysfunction indication, working on brain melanocortin receptors rather than peripheral blood flow.
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II that activates MC4R (and to a lesser extent MC3R) in the hypothalamus to drive sexual desire and arousal centrally. Marketed as Vyleesi, it was FDA-approved in June 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women on the strength of the Phase 3 RECONNECT program. Unlike PDE5 inhibitors such as sildenafil, which act on peripheral vasculature, PT-141 addresses arousal upstream in the central nervous system, and it is widely used off-label in men for erectile dysfunction and libido.
Class
Synthetic cyclic heptapeptide (melanocortin receptor agonist)
Half-life
~2-2.7 hours (peak plasma ~1 hour; central effect onset 30-60 minutes)
Routes
Subcutaneous injection
Category
Sexual Health & Melanocortin
Researched benefits
What it's studied for
Central sexual arousal and desire
PT-141 activates MC4R-expressing neurons in the hypothalamic paraventricular nucleus and medial preoptic area to generate the upstream arousal signal itself, increasing sexual motivation and approach behavior. This central mechanism is effective regardless of vascular status, unlike PDE5 inhibitors.
FDA-approved treatment for HSDD in women
In the Phase 3 RECONNECT trials, bremelanotide 1.75 mg subcutaneous significantly improved sexual desire scores and reduced HSDD-related distress versus placebo in premenopausal women, forming the basis of its 2019 FDA approval as Vyleesi.
Off-label male erectile dysfunction
Because the MC4R arousal architecture is conserved across sexes, PT-141 is used off-label in men. Early Phase 2 data in PDE5-inhibitor non-responders showed roughly 34% achieving erections versus 9% on placebo, making it a candidate where sildenafil-class drugs fail.
Non-hormonal, non-vascular approach
PT-141 works through central melanocortin signaling rather than androgen receptors or peripheral cGMP pathways, so it can address desire and arousal disorders where the physiologic machinery is intact but the central trigger is not firing, including cases linked to SSRI use or post-finasteride syndrome (evidence here is anecdotal/case-series).
On-demand dosing
The short half-life and 30-60 minute onset make PT-141 an as-needed compound taken before anticipated activity, similar to PDE5 inhibitors and unlike chronically dosed interventions such as testosterone replacement.
Mechanism
How it works
PT-141 is a synthetic cyclic heptapeptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). It binds the melanocortin receptor family with selectivity favoring MC4R, with moderate MC3R activity and low residual MC1R activity. It was derived from Melanotan II specifically to isolate the sexual-function effect while minimizing the strong MC1R-driven pigmentation of the parent compound.
The critical substrate is MC4R-expressing neurons in the paraventricular nucleus of the hypothalamus. Activation drives downstream oxytocinergic signaling, medial preoptic area activation that promotes sexual motivation, dopaminergic activation in mesolimbic reward circuits that amplifies the subjective interest component of arousal, and pro-erectile autonomic output to sacral ganglia in men. This entire cascade sits upstream of the peripheral vascular machinery that PDE5 inhibitors target.
Because the MC4R arousal pathway is relatively sex-agnostic and conserved across sexes, the same molecule produces effects on sexual motivation in both women and men. The MC4R pathway is simultaneously the central satiety circuit, which is why MC4R activation also modestly suppresses appetite and produces mild nausea as a direct pharmacodynamic consequence rather than an off-target effect.
Following a 1.75 mg subcutaneous injection, peak plasma concentration occurs at roughly 1 hour with a half-life near 2.7 hours. Subjective sexual effects typically begin 30-60 minutes post-injection and persist for 4-8 hours, and blood pressure effects normalize by about 12 hours. The short half-life is deliberate, keeping the drug on-demand rather than chronically dosed and limiting cumulative exposure.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Research PT-141 typically ships as a white lyophilized powder in 2 mg or 10 mg vials. A common approach is 10 mg reconstituted with 2 mL bacteriostatic water, yielding 5 mg/mL: 0.5 mg = 0.1 mL (10 units), 1.0 mg = 0.2 mL (20 units), 1.5 mg = 0.3 mL (30 units), 1.75 mg = 0.35 mL (35 units), 2.0 mg = 0.4 mL (40 units) on a U-100 insulin syringe. Some users prefer 10 mg + 1 mL BAC water (10 mg/mL) for smaller injection volumes. Run water down the vial wall rather than onto the powder, do not shake, swirl gently until clear, refrigerate at 2-8C, use within 30 days, never freeze, and protect from light.
Beginner
- Dose
- 0.5 mg
- Frequency
- No more than once per 72 hours for the first 2-3 uses, then no more than once per 24 hours
- Timing
- 45-60 minutes before anticipated sexual activity
- Duration
- As needed
- Route
- Subcutaneous (abdomen or thigh)
Starting low identifies whether you are a nausea responder needing pre-medication or a clean responder who can escalate. Empty bladder, eat a small low-fat snack, stay hydrated, avoid alcohol within 3 hours. Obtain baseline resting blood pressure on two separate days first.
Intermediate
- Dose
- 1.0-1.75 mg
- Frequency
- Maximum once per 24 hours, no more than 8 doses per month
- Timing
- 45-60 minutes before sexual activity
- Duration
- As needed (on-demand)
- Route
- Subcutaneous
Standard on-demand protocol after tolerance is established, titrating from 0.5 mg (weeks 1-2) to 1.0 mg (weeks 3-4) to 1.0-1.75 mg thereafter. 1.75 mg is the FDA-approved Vyleesi dose. Nausea mitigation: ondansetron 4-8 mg 30 minutes prior, ginger 500-1000 mg, a light protein snack, or dosing at bedtime.
Advanced
- Dose
- 1.75-2 mg
- Frequency
- Up to once per 24 hours (FDA cap of 8 doses/month; some off-label users exceed this)
- Timing
- 45-60 minutes before sexual activity
- Duration
- As needed
- Route
- Subcutaneous
Not recommended without medical oversight. Diminishing returns above 2 mg, where nausea and blood pressure effects scale faster than sexual response. Frequent users should monitor skin monthly, see a dermatologist annually, and take a 4-week washout every 3-4 months to limit cumulative MC1R exposure.
- On-demand only: daily dosing provides no additional efficacy and amplifies hyperpigmentation and cumulative blood pressure exposure.
- The FDA-approved Vyleesi dose is a fixed 1.75 mg regardless of body weight, delivered by single-use autoinjector.
- There is no evidence of pharmacologic tolerance at MC4R with intermittent use; apparent waning effect usually reflects dose creep or contextual factors rather than receptor tolerance.
- Subcutaneous route only; the earlier intranasal formulation was abandoned due to blood pressure concerns.
- Stop completely for any new or changing pigmented skin lesion, persistent blood pressure elevation not resolving within 12 hours, chest pain or cardiovascular symptoms, or severe uncontrollable nausea.
Evidence
Research & clinical studies (4)
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
The two Phase 3 RECONNECT trials (n=1,247) demonstrated that bremelanotide 1.75 mg subcutaneous significantly improved sexual desire scores and reduced related sexual distress versus placebo in premenopausal women with HSDD.
PMID 31599840The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women
Describes how bremelanotide activates melanocortin-4 receptors in the hypothalamic medial preoptic area, increasing dopamine release through the excitatory sexual response pathway.
PMID 33455598Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide
Responder analyses found bremelanotide 1.75 mg achieved statistically significant improvements versus placebo across seven sexual function endpoints, establishing thresholds used in the Phase 3 registration program.
PMID 31277966Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Reviews approved therapeutic peptides as promising for metabolic, endocrine, and aesthetic conditions while noting many novel unapproved peptides lack sufficient human safety data.
PMID 42123471Combinations
Stacking & blends
PT-141 + PDE5 inhibitor (male ED)
Cover both central arousal and peripheral vascular components of erectile dysfunction
PT-141 1-1.5 mg SC 45 minutes before combined with tadalafil 5-10 mg (2 hours before) or sildenafil 25-50 mg addresses the central trigger and peripheral blood flow together. Blood pressure effects are additive, so separate doses by 2+ hours and monitor BP on the first combination uses.
PT-141 + Oxytocin
Amplify the emotional and bonding dimension of the sexual experience
Oxytocin (sublingual 10-30 IU) is mechanistically synergistic because PT-141's MC4R activation itself drives central oxytocin release; the combination is complementary though evidence remains largely anecdotal.
PT-141 + Testosterone replacement
Restore desire in hypogonadal men where hormonal optimization alone is insufficient
PT-141 addresses the central arousal circuit while testosterone restores the androgen-dependent libido substrate, appropriate when normalized testosterone still leaves diminished desire.
PT-141 + Kisspeptin-10
Target sexual function at multiple levels of the neuroendocrine hierarchy
PT-141 provides direct melanocortin receptor activation for arousal at the CNS level while kisspeptin-10 stimulates the HPG axis via pulsatile LH and GnRH release, supporting the hormonal underpinning of libido (preclinical rationale).
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Uncontrolled hypertension (SBP >160 or DBP >100)
- Established cardiovascular disease (prior MI, stroke, heart failure, significant CAD, unstable angina)
- Significant peripheral vascular disease
- Pregnancy
- Breastfeeding
- Known hypersensitivity to bremelanotide
- Concurrent naltrexone (per vendor caution)
Nausea is the single most common adverse event, usually beginning 30-60 minutes post-injection and resolving within 2-4 hours; it typically attenuates with subsequent doses and can be managed with pre-medication, timing, and a light snack. Transient blood pressure elevation peaks at 2-4 hours and resolves by about 12 hours, so baseline and early BP monitoring are advised. Residual MC1R activity can cause dose-dependent hyperpigmentation (darker or new freckles, enlarging moles, facial/gum/areolar darkening) that is generally slowly reversible but occasionally persistent; frequent users should perform monthly skin self-exams, have annual dermatology checks, and use aggressive sun protection. Response is heterogeneous: responders often describe dramatic effects while non-responders notice almost nothing, and researchers have questioned whether the average effect size in the approved indication is clinically meaningful relative to the side-effect burden.
FAQ
PT-141 (Bremelanotide) — common questions
What is PT-141 and how does it work?
PT-141 (bremelanotide) is a synthetic cyclic 7-amino-acid melanocortin receptor agonist that works centrally in the brain, specifically on MC4R-expressing neurons in the hypothalamus, to enhance sexual desire, arousal, and responsiveness. It was FDA-approved as Vyleesi in June 2019 for acquired, generalized HSDD in premenopausal women.
How is PT-141 different from Viagra or Cialis?
PDE5 inhibitors like sildenafil and tadalafil act peripherally in the corpus cavernosum to maintain erectile blood flow once arousal has begun. PT-141 acts centrally, activating MC4R receptors in the brain to generate the arousal signal itself. This means PT-141 can address low desire and arousal disorders that PDE5 inhibitors cannot, and the two are sometimes combined for additive central plus peripheral coverage.
Can men use PT-141?
Yes, off-label. FDA approval is specifically for premenopausal women with HSDD, but the MC4R mechanism is not sex-specific. Early Phase 2 data in PDE5-inhibitor non-responders showed about 34% achieving erections versus 9% on placebo. Typical off-label male dosing is 1-1.75 mg SC 45-60 minutes before activity; this use is not FDA-evaluated.
What is the typical dose?
The FDA-approved Vyleesi dose is 1.75 mg subcutaneous, taken as needed at least 45 minutes before anticipated activity, with a maximum of one dose per 24 hours and 8 doses per month. First-time users often start at 0.5 mg to assess nausea tolerance and titrate up; doses above 2 mg show diminishing returns.
What are the side effects?
The most common is nausea, affecting roughly 40% of users, usually starting 30-60 minutes after injection and resolving within a few hours. Others include flushing, injection-site reactions, headache, and a transient blood pressure rise. With repeated use, residual MC1R activity can cause dose-dependent hyperpigmentation. PT-141 is contraindicated in uncontrolled hypertension and established cardiovascular disease.
Does PT-141 cause permanent tanning or moles?
PT-141 has far less MC1R activity than its parent Melanotan II, but residual activity can cause dose-dependent hyperpigmentation with repeated use, appearing as darker or new freckles, enlarging moles, or facial and areolar darkening. It is generally slowly reversible with discontinuation, though some users experience persistent patches. Frequent users should do monthly skin self-exams, annual dermatology checks, periodic washouts, and use SPF 50+.
How long does it last?
Peak plasma concentration occurs around 1 hour with a half-life near 2.7 hours. Subjective sexual effects typically begin 30-60 minutes after injection and persist for 4-8 hours, making PT-141 an on-demand rather than daily-dosed drug. Blood pressure effects normalize by about 12 hours.
Is PT-141 FDA-approved and legal?
Yes. Bremelanotide is FDA-approved as Vyleesi for HSDD in premenopausal women and is available by prescription. Research-grade PT-141 sold through peptide suppliers is the same molecule but classified for laboratory use only and is not the FDA-approved prescription product intended for human use.
